✨ Free AI Report
Korro Bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Korro Bio, Inc.
Company Research

Korro Bio, Inc.: Business Overview, Financials & Competitive Analysis

Korro Bio is a clinical-stage biopharmaceutical company focused on developing a novel class of genetic medicines based on RNA editing to treat rare and highly prevalent diseases. The company harnesses the body's natur...

Analyst-debate audio for Korro Bio, Inc.

AskCyborg analysts argue the bull and bear cases for Korro Bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

RNA editing biotech with differentiated platform technology, attractive valuations following recent pullback, but pre-revenue...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Gene Therapy & RNA Therapeutics
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Korro Bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Korro Bio, Inc. Overview

Pro stress-test →

Korro Bio is a clinical-stage biopharmaceutical company focused on developing a novel class of genetic medicines based on RNA editing to treat rare and highly prevalent diseases. The company harnesses the body's natural RNA editing process to effect precise, transient single base edits, differentiating itself from traditional DNA-based gene therapies.

Strategic Profile

Pro stress-test →

Korro's competitive advantage lies in its proprietary RNA editing platform that enables broader therapeutic reach compared to DNA editing approaches while maintaining transient effects. The company has established a strategic collaboration with Novo Nordisk for cardiometabolic diseases and is advancing a diverse pipeline including KRRO-110 for Alpha-1 Antitrypsin Deficiency, with programs in Parkinson's disease, ALS, and pain indications.

Competitive Landscape

Pro stress-test →

Korro Bio competes in the RNA therapeutics space against established gene therapy companies and emerging RNA editing platforms. Key competitors include Editas Medicine and CRISPR Therapeutics (DNA CRISPR editing), Sarepta Therapeutics (gene therapy), and other RNA-based approaches. Korro's transient RNA editing approach positions it as differentiated from permanent DNA-based competitors, though clinical validation remains ongoing.

Industry Context

Korro Bio, Inc. operates in Biopharmaceuticals - Gene Therapy & RNA Therapeutics.

Key facts

Founded: 2018 · Headquarters: Cambridge, Massachusetts · Employees: 87 · Revenue: $0M · Market cap: $112.6M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Korro Bio, Inc..

  • KRRO-110 (for Alpha-1 Antitrypsin Deficiency) demonstrated functional protein production in Phase 1/2a trials but did not meet projected functional protein levels as of November 2025
  • Stock trading near 52-week lows ($11.96 as of Feb 5, 2026) with average analyst price target of $17.34/share suggesting 54% upside potential
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Clear Street upgraded Korro Bio to Buy rating from Hold
  • November 2025KRRO-110 Phase 1/2a REWRITE trial showed functional protein production in AATD patients but below projected levels
  • +2 moreTrack every material event for Korro Bio, Inc. as it happens. Explore monitoring →
Get alerted when Korro Bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CRISPR TherapeuticsDNA-based CRISPR gene editing for genetic diseases→Editas MedicineDNA-based CRISPR-Cas9 gene editing platform→Sarepta TherapeuticsGene therapy and RNA therapeutics for rare diseases→

Compare Korro Bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Korro Bio, Inc. operates in Biopharmaceuticals - Gene Therapy & RNA Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Gene Therapy & RNA Therapeutics research →
NEW · MCP server

Ask your AI assistant about Korro Bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Korro Bio, Inc. and its top competitor on Cyborg Score”
“What did Korro Bio, Inc. do this quarter?”
“Is Korro Bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Korro Bio, Inc. do?+
Korro Bio is a clinical-stage biopharmaceutical company focused on developing a novel class of genetic medicines based on RNA editing to treat rare and highly prevalent diseases. The company harnesses the body's natur...
What is Korro Bio, Inc.'s Cyborg Score?+
Korro Bio, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Korro Bio, Inc.'s main competitors?+
Named competitors include CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Korro Bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Korro Bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Korro Bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Gene Therapy & RNA Therapeutics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5Korro Bio, Inc.